The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Company expects strong organic growth in sales, EBITDA in 2022
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
The joint initiative is called J-ARC Healthcare Solutions
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida
Subscribe To Our Newsletter & Stay Updated
